Pfizer have won the battle to acquire American biotech company Medivation in a $14billion deal (£11billion). However, EdenTree’s Ketan Patel tells the Daily Express that the long term question for investors is whether Pfizer has overpaid for Medivation.
In the Financial Times, Charlie Carnegie, research director at Arisaig Partners, and Eric Pedersen, head of responsible investments at Nordea Asset Management, discuss divesting from emissions-heavy dairy and meat industries. Link
In Trustnet, Vincent Ropers, co-manager of the TB Wise Multi-Asset Growth fund, shares his thoughts on where to find value away from Silicon Valley tech stocks. “The sky hasn’t...
